• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Venture Capital Matters

#VentureCapital: VC meets social media

  • Pitch a Startup
  • Market Reports
  • Technologies
    • Technology Events
  • Domain Names for Startups
  • About
  • Contact

TISSIUM Closes €39M Series B Funding Round

November 19, 2019 By 3v.org Leave a Comment

TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today it has raised €38.75 million ($42.78 million) in a Series B round of funding. This funding round comprises new investors BNP Paribas Développement, the European Investment Fund (EIF), M&L Investments, ValQuest Partners in addition to TISSIUM’s returning investors Bpifrance, CM-CIC Innovation, CapDecisif Management, Omnes Capital and Sofinnova Partners.

The funding raised in this round will be used to support the Company’s global expansion of its platform of polymers across a variety of therapeutic fields, including nerve repair, cardiovascular and gastroenterology, among others.

The TISSIUM platform leverages proprietary technology, initially developed at the Massachusetts Institute of Technology (MIT) & Brigham and Women’s Hospital, Harvard Medical School, that serves as the foundation of a family of fully synthetic, biomorphic and programmable polymers. These polymers are designed to be used inside the body as sealants, adhesives, barriers, plugs or as a vehicle for drug delivery, as well as implantable devices created outside of the body using 3D printing technology.

In addition to supporting the growth of the platform, the funding is expected to support the broader strategy of creating a streamlined clinical development and regulatory process across multiple geographies. While the company remains headquartered in Paris, these efforts will also be focused towards the U.S. out of its newly opened Boston affiliate office.

Streamlined innovation and product development will also be simplified as a result of the completion of TISSIUM’s state-of-the-art manufacturing facility in Lille, France.

In addition, following the completion of the Series B, Jay Watkins, a serial Medtech entrepreneur and executive, is joining TISSIUM’s Board of Directors as Independent Chairman.

Christophe Bancel, CEO of TISSIUM, said: « This new round of funding is a testament to the support we continue to receive from investors for our strategy and vision for the broad TISSIUM ecosystem of products that we have in development. We look forward to moving swiftly towards multiple verticals and expanding into new clinical fields in the coming months.

We are thrilled to have Jay joining our board as Chairman. He brings tremendous experience and depth in building innovative Medtech companies into next generations leaders and will allow us to shape and expend our ecosystem into multiple verticals. I take the opportunity to thank our co-founder, Bernard Gilly, co-founder and Chairman of iBionext, who has led the company as its Chairman since our inception. »

Jay Watkins, Chairman of TISSIUM, added: « I am delighted to join TISSIUM as Chairman. I have been impressed with the breadth of applications for its biomorphic programmable polymers across a wide range of therapeutic fields. The organization has already demonstrated its ability to innovate and create novel product opportunities and I look forward to working with the team to extend our impact in the Medtech space. »

About TISSIUM:
TISSIUM is a privately-owned life sciences company based in Paris, France that is dedicated to the rapid development and commercialization of a unique biopolymer platform to address various unmet clinical needs.

The company’s platform is based on a proprietary polymer family with unique properties including the ability to conform to, and integrate with, surrounding tissue to enable natural healing. Furthermore, the modular design of the polymers enables customization to match tissue-specific requirements for different therapeutic areas. The company also develops delivery and activation devices for enhanced performance and usability of its family of polymers.

The Company’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013. For more information, please visit: www.TISSIUM.com

Related

Filed Under: PR Tagged With: biomorphic programmable polymers, life science

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

RSS Market Research Media

  • America’s 100 largest housing markets are overpriced
  • How do media companies perform in digital transformations?
  • A six-step forecasting methodology
  • New skills will be required for the future world of work
  • Two biggest barriers to wider adoption of XR are user experience and limited content
  • The current market value for AR/VR/MR is around $30.7B, and the worldwide market may rise to $300B by 2024
  • Global asset classes compared by market cap in 2021
  • Russian oil production succumbing to the impact of Western sanctions
  • Russia’s default on its foreign debt is around the corner
  • BRIC Investment Funds Have Taken a Beating This Year

RSS Market Analysis

  • Another pandemic may be on the horizon: antimicrobial resistance
  • Low-carbon fuels will be essential for decarbonization
  • Blue hydrogen becoming increasingly cost competitive
  • The construction industry is responsible for 11% of the world’s man-made carbon emissions
  • Military Applications of Quantum Technology
  • New Technologies to Disrupt Traditional Renewable Fuels
  • Australia approves a drought-tolerant genetically modified strain of wheat for use in food
  • The Pentagon’s FY2023 budget request for hypersonic-related research is $4.7 billion
  • Middle East and North Africa region’s economies grew by 5.8% in 2021
  • Job openings hit a record high March

RSS Technologies

  • Cloudflare Unveils New SQL Database Offering
  • Cloudflare announces Workers for Platforms
  • Intel is rolling out new processors designed for data centers
  • EU moves to wean itself off Russian fossil fuels
  • A New Hydrogen-Powered Behemoth
  • BAE Systems to Bring Next-Generation Electric Drive System to Heavy-Duty Industrial Vehicle Market
  • MEMS Speakers Are Replacing Balanced Armature Speakers
  • Trends in data and analytics
  • Apple takes another step towards EV development
  • French company captures methane leaking from abandoned mines

Copyright © 2018 3V.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT